- Congress considered proposals to strengthen FDA authority regarding medical device regulation and minimum standards.
- Policymakers are considering ways to influence the drug market, including potential changes to patent rights and the FDA approval process.
Congress and the Senate are considering legislation affecting FDA submissions and drug patent rights.
2 reports, 2 independent
Updated 20:15
Still developing
- Reports
- 2
- Developments
- 2
- Repetition
- 0%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Congress and the Senate are considering legislation affecting FDA submissions and drug patent rights.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Senate advances FDA funding bill to the House1 source
Congress and Senate report on bills concerning FDA submissions and drug patents.1 source
Keep exploring
The entities involved
- FDA
-
Congress
US record label; imprint of Congress Record Corp.
-
senate
type of legislative body, often the upper house or chamber of a bicameral legislature
Related events
- The FDA is a U.S. government agency, a basic descriptive fact about the regulator.
- FDA failed to update warning labels despite confirmed risks associated with a product.
- FDA approval coincided with Donald Trump's press conference on November 11, 2026.
- Forbes reported on recent drug filings submitted to the FDA and the European Medicines Agency.
- The administration has signed an executive order and issued priority vouchers to accelerate the drug approval process through the FDA.